Beckman Coulter, an indirect wholly-owned subsidiary of Danaher Corporation (NYSE:DHR), announced today that it has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics.
Beckman Coulter Diagnostics announces the publication of research results in the Clinical Biochemistry journal that identifies the precise magnitude of change in cardiac troponin required for early diagnosis of a heart attack (myocardial infarction, or MI), utilizing its Access AccuTnI+3 troponin I blood test. Beckman Coulter’s troponin-I assay has been clinically proven through a large, multi-center study and is the only troponin assay currently cleared by the U.S. Food and Drug Administration (FDA) that is directly aligned with the agency’s October 2010 guidance to manufacturers of troponin tests.
Beckman Coulter Diagnostics received US Food and Drug Administration (FDA) 510(k) clearance for its UniCel DxH v3.0 software, which supports automated connectivity of the diagnostic use. The clearance enables laboratories to connect up to three DxH 800 analyzers to a DxH Slidemaker Stainer to create a customized, scalable workflow solution.
DRG International, a leading international medical diagnostic company, will showcase its DRG® Aldosterone ELISA Kit at the 2015 AACC in Atlanta, Georgia on July 27-30. The DRG International Aldosterone ELISA is for measurement of Aldosterone in serum, plasma, and urine.
The DRG:Hybrid-XL® will be showcased as the centerpiece of DRG International’s display at the 2015 AACC conference in Atlanta, Georgia. The AACC, held from July 27-30, is the premiere conference of its type, welcoming all the leaders in the clinical chemistry field year after year. The DRG:Hybrid-XL® desktop analyzer is now available in the market worldwide and has revolutionized automation for laboratories. It is suitable for small to medium-sized laboratories, providing diagnostic services to research facilities in hospitals, clinics and large medical practices.
The DRG® 25-OH Vitamin D (total) ELISA, an enzyme immunoassay for the measurement of total 25-OH Vitamin D (Vitamin D2 and Vitamin D3) in both serum and plasma, will be a highlight of the 2015 American Association for Clinical Chemistry (AACC) Conference on July 27-30 in Atlanta, Georgia.
DRG International’s Renin (Active) ELISA for testing of active Renin in human EDTA plasma will be on display at the AACC’s 2015 show Atlanta, Georgia on July 27-30. The DRG® Renin active ELISA test is accurate in testing for certain types of hypertension and has been utilized by labs world-wide.
Total Lab Care (TLC), an ELITechGroup specialized consultant provider for Physician Office Laboratories (POLs) announces that its Laboratory Essentials Course has been approved for 3.5 hours of P.A.C.E. continuing education credits. Course participants will learn or refresh their memory on the basics of the clinical laboratory in a self‐paced environment. This web‐based interactive training program, comprised of 10 individual lessons, reviews CLIA rules and regulations and laboratory operations from pre‐analytical to post‐analytical processes including laboratory testing requirements (i.e. pipetting, safety, equipment operation, etc.).
EMD Millipore Introduces New High-Performance Water Purification Systems with 24/7 Real-Time Monitoring and Remote Control • New AFS® 40E / 80E / 120E and 150E systems fulfill pure water needs for one or several high-throughput clinical analyzers.
Kathy Holland, MD is the Director of Operations and Medical Director of Equitech Enterprises which supplies custom normal and disease state blood collections. Dr. Holland has extensive experience in the human blood collection field. From being a small enterprise, she has increased its donor base to include a wide range of age, ethnicity, and disease state. All collections receive viral screening including HIV, Hepatitis B&C, Syphilis, and other selected markers. All donors receive, and are qualified by, a fully comprehensive three page Donor Health Questionnaire in which data and demographics information is given on request. They provide custom specimen collections or bulk quantities ranging from a single unit to hundreds of liters. Equitech Enterprises, Inc. is FDA Approved, and IRB Certified.
KNF Neuberger, Inc. announces an extension to the line of brushless DC powered NFB boxer pumps with the addition of two compact, powerful models. The new NFB 5 and NFB 25 feature low pulsation, gentle transfer of liquids from 5 – 300 mL/min per head, and cost savings thanks to efficient design and long product life.
MBS MAB230P, monoclonal antibody to the polyhistidine (HIS) tag has been incorporated into the second generation Forte Bio Anti-HIS biosensors for rapid quantitative measurement of HIS tagged proteins. MAB230P was selected by ForteBio after demonstrating high specificity and excellent sensitivity, detecting HIS tagged proteins in nanogram quantities. The antibody is broadly reactive, recognizing HIS tags of 4X or greater, engineered at either the N- or C-terminus of the protein. The internal development and production of MAB230P allows MBS to maintain the highest quality standards and the ability to offer the lowest price in the marketplace.
Remember when the doctor came to your house? Well, your grandmother does. Now doctors are coming to the workplace. Not only is it convenient for employees—saving time and keeping them nearby—but, executives are seeing company savings in a time of rising healthcare costs.
Seralite® - FLC is a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum as an aid to the diagnosis and management of multiple myeloma. The assay provides an accurate picture of disease status in 10 minutes. Using a simple to use, portable, rapid test, clinicians are able to monitor patients in “real time” supporting faster decision making
Yantai Addcare Bio-Tech Limited Company is a high-tech enterprise engaged in the development, production and sales of fully automated liquid handling systems, immunoassay workstations and related products. We are currently the only manufacturer in China holding independent intellectual property rights in this product segment.
Background Immunofluorescence Assays (IFA) used for screening of autoimmune diseases have a number of challenges. When performed manually, IFA is laborious, subjective and poorly standardized. With the advent of multiplex technologies in early-2000, the autoimmune community thought it had found a solution, until it became evident that multiplex technologies had limitations, which made them poor candidates for antinuclear antibody screening (ANA). Today, there are 30 to 50 clinically significant autoantibodies outside of the HEp-2 cell, which currently have no method for screening.1
Every baby born that enters this world, arrives with an umbilical cord in tow. For those babies born addicted to drugs, that umbilical cord is now a key connection—a hard to hide clue—for identifying what drugs are coursing through a newborn’s veins. The drug(s) detected will help physicians determine the best treatment and what withdrawal symptoms to expect.
“There is no cure for HHT, yet if we can find new genetic modifiers or new genes, then we can potentially find novel therapeutics to treat these patients,” explains an enthusiastic Whitney Wooderchak-Donahue, PhD, a researcher with the University of Utah and ARUP Laboratories. Last week, she received the 2015 Young Scholar Research Grant ($30,000) for her research proposal that involves focusing on patients’ transcripts (the RNA in the cell) via their blood samples to identify genetic modifiers in Hereditary Hemorrhagic Telangiectasia (HHT).
As thousands turn out this spring to run and walk in memory of loved ones lost to breast cancer, behind-the-scene researchers are running a race of a different kind to help physicians treat their cancer patients. It is a race to acquire genetic knowledge, and success is dependent on collaborations and expertise from researchers worldwide.
DRG International, a leading international medical diagnostic company, will showcase the NEW DRG® Hepcidin 25 (bioactive) HS (High Sensitive) ELISA Kit (EIA-5782) at the 2015 AACC in Atlanta, Georgia from July 27-30. As the first of its kind to market, this kit accurately detects bioactive Hepcidin levels as an additional marker to aid in identifying a variety of disorders. In recent years, a large number of publications identify Hepcidin as a factor in regulating the amount of iron in humans. Unbalanced iron level can lead to many common medical conditions including anemia and iron overload disease, and can occur in chronic kidney disease, inflammation, or diabetes mellitus
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right